Mucosal Adjuvants: Opportunities and Challenges

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2016 May 10

PMID 27159278

Citations 22

Authors

Lingbin Zeng

Affiliations

Soon will be listed here.

Abstract

Most pathogens access the body via mucosal surfaces. Mucosal vaccination is a highly effective and recommended method to prevent mucosally transmitted infections. Compared with immunization via intramuscular injection, mucosal immunization offers remarkable advantages, including non-invasiveness, low costs and reduced risk of transmission of blood-borne diseases, which make it more acceptable to human beings, especially to young children. However, only few mucosal vaccines are licensed for human, which is mainly due to the deficiency of safe and effective mucosal adjuvants. Adjuvants, as important components of most vaccines, are essential to enhance immunity and induce immune memory. The development of mucosal adjuvants, unfortunately, has been severely hampered by research strategies based on empiric trials and non-comprehensive methods for safety evaluation. Therefore, changing the research and development strategies of mucosal adjuvant field from empiricism based discovery to rational design based invention is highly demanded. The change of strategies mainly depends upon clarification of mechanism of mucosal adjuvant activity though a combination of life science, information science and materials science.

Citing Articles

Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2.

Lin Y, Liao X, Cao X, Zhang Z, Wang X, He X J Clin Invest. 2025; 135(5).

PMID: 39808503 PMC: 11870729. DOI: 10.1172/JCI175233.

Preliminary Study on Type I Interferon as a Mucosal Adjuvant for Human Respiratory Syncytial Virus F Protein.

Hu H, Zhang L, Cao L, Jiang J, Shi Y, Guo H Vaccines (Basel). 2024; 12(11).

PMID: 39591199 PMC: 11598909. DOI: 10.3390/vaccines12111297.

Mucosal immunization with the lung Lactobacillus-derived amphiphilic exopolysaccharide adjuvanted recombinant vaccine improved protection against P. aeruginosa infection.

Zhang H, Sheng S, Li C, Bao X, Zhao L, Chen J PLoS Pathog. 2024; 20(11):e1012696.

PMID: 39556597 PMC: 11611261. DOI: 10.1371/journal.ppat.1012696.

Importance of adjuvant selection in tuberculosis vaccine development: Exploring basic mechanisms and clinical implications.

Gyu Choi H, Kwon K, Shin S Vaccine X. 2023; 15:100400.

PMID: 37965276 PMC: 10641539. DOI: 10.1016/j.jvacx.2023.100400.

Assessing the Adjuvant Effect of Layered Double Hydroxides (LDH) on BALB/c Mice.

Govea-Alonso D, Garcia-Soto M, Mendoza-Perez E, Farfan-Castro S, Fuente D, Gonzalez-Ortega O Materials (Basel). 2023; 16(15).

PMID: 37570172 PMC: 10419364. DOI: 10.3390/ma16155467.

References

Petrovsky N . Vaccine adjuvant safety: the elephant in the room. Expert Rev Vaccines. 2013; 12(7):715-7. DOI: 10.1586/14760584.2013.811198. View

Gavin A, Hoebe K, Duong B, Ota T, Martin C, Beutler B . Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science. 2006; 314(5807):1936-8. PMC: 1868398. DOI: 10.1126/science.1135299. View

Srivastava A, Gowda D, Madhunapantula S, Shinde C, Iyer M . Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles. APMIS. 2015; 123(4):275-88. DOI: 10.1111/apm.12351. View

Bielinska A, Makidon P, Janczak K, Blanco L, Swanson B, Smith D . Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant. J Immunol. 2014; 192(6):2722-33. PMC: 3948110. DOI: 10.4049/jimmunol.1301424. View

Esser M, Marchese R, Kierstead L, Tussey L, Wang F, Chirmule N . Memory T cells and vaccines. Vaccine. 2003; 21(5-6):419-30. DOI: 10.1016/s0264-410x(02)00407-3. View

Coffman R, Sher A, Seder R . Vaccine adjuvants: putting innate immunity to work. Immunity. 2010; 33(4):492-503. PMC: 3420356. DOI: 10.1016/j.immuni.2010.10.002. View

McCluskie M, Davis H . CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol. 1998; 161(9):4463-6. View

Abraham S, St John A . Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 2010; 10(6):440-52. PMC: 4469150. DOI: 10.1038/nri2782. View

Pasare C, Medzhitov R . Control of B-cell responses by Toll-like receptors. Nature. 2005; 438(7066):364-8. DOI: 10.1038/nature04267. View

10.

Lycke N . Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol. 2012; 12(8):592-605. DOI: 10.1038/nri3251. View

11.

Olafsdottir T, Lindqvist M, Harandi A . Molecular signatures of vaccine adjuvants. Vaccine. 2015; 33(40):5302-7. DOI: 10.1016/j.vaccine.2015.04.099. View

12.

Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M . Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A. 2009; 106(19):7962-7. PMC: 2674105. DOI: 10.1073/pnas.0903181106. View

13.

Sjokvist Ottsjo L, Flach C, Clements J, Holmgren J, Raghavan S . A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect Immun. 2013; 81(5):1532-40. PMC: 3647992. DOI: 10.1128/IAI.01407-12. View

14.

Neutra M, Kozlowski P . Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006; 6(2):148-58. DOI: 10.1038/nri1777. View

15.

Fujihashi K, Sato S, Kiyono H . Mucosal adjuvants for vaccines to control upper respiratory infections in the elderly. Exp Gerontol. 2014; 54:21-6. PMC: 3989367. DOI: 10.1016/j.exger.2014.01.006. View

16.

Nedrud J, Bagheri N, Schon K, Xin W, Bergroth H, Eliasson D . Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity. PLoS One. 2014; 8(12):e83321. PMC: 3877028. DOI: 10.1371/journal.pone.0083321. View

17.

Porgador A, Staats H, Faiola B, Gilboa E, Palker T . Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J Immunol. 1997; 158(2):834-41. View

18.

Peppoloni S, Ruggiero P, Contorni M, Morandi M, Pizza M, Rappuoli R . Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev Vaccines. 2003; 2(2):285-93. DOI: 10.1586/14760584.2.2.285. View

19.

Baldwin S, Bertholet S, Reese V, Ching L, Reed S, Coler R . The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol. 2012; 188(5):2189-97. PMC: 3288309. DOI: 10.4049/jimmunol.1102696. View

20.

Nagpal G, Gupta S, Chaudhary K, Dhanda S, Prakash S, Raghava G . VaccineDA: Prediction, design and genome-wide screening of oligodeoxynucleotide-based vaccine adjuvants. Sci Rep. 2015; 5:12478. PMC: 4515643. DOI: 10.1038/srep12478. View